B7-H3 (CD276), an immune checkpoint molecule involved in tumor progression, along with receptors EGFRvIII and IL13Rα2, are highly overexpressed in GBM and associated with worse prognoses, making them attractive therapeutic targets [18,63]. This evidence concerns the gene CD276 and glioblastoma.